Korea Research Institute of Chemical Technology (KRICT) and PINOTBIO have patented benzothiazole and benzimidazole derivatives acting as NAD-dependent protein deacetylase sirtuin-7 (SIRT7) inhibitors reported to be useful for the treatment of cancer, among other disorders.

Researchers at the University of Washington and the Fred Hutchinson Cancer Center have reported the development of an in vivo model of macrophage infiltration of the tumor microenvironment (TME) in melanoma and how infiltration affects tumor progression.

Ascentage Pharma has discovered sulfonyl benzamide derivatives acting as apoptosis regulator Bcl-2 and/or Bcl-2 (G101V mutant) inhibitors reported to be useful for the treatment of cancer.

The Consiglio Nazionale delle Ricerche and the Societa Industria Farmaceutica Italiana SpA (SIFI) have described new peptides acting as vascular endothelial growth factor receptor 1 (VEGFR-1; FLT1) and VEGFR-2 inhibitors reported to be useful for the treatment of cancer, choroidal neovascularization, hematopoiesis disorders, macular edema, central retinal vein occlusion, central serous retinopathy, diabetic retinopathy and wet macular degeneration, among other disorders.

Yangtze River Pharmaceutical Group and Shanghai Haiyan Pharmaceutical Technology have divulged new morpholine derivatives acting as P2X purinoceptor 3 (P2RX3; P2X3) antagonists and reported to be useful for the treatment of cancer, pain, cough, depression, anxiety and genitourinary, gastrointestinal and immunological disorders, among other disorders.

Floratek has presented new chromen-4-one derivatives comprising a phosphonium quaternary group reported to be useful for the treatment of cancer.

Ferroptosis, a type of programmed cell death dependent on iron and characterized by the accumulation of lipid peroxides, is limited in some tumors. Scientists have identified a glutathione (GSH)-independent axis centered mainly on the ferroptosis suppressor protein 1 (FSP1) as responsible for this suppression.

A proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF) are two ligands of the tumor necrosis factor (TNF) superfamily with a crucial regulatory role in B-cell maturation and differentiation. APRIL and BAFF action occurs through binding to three TNF receptors: TACI (transmembrane activator and Ca2+ modulator interactor), B-cell maturation antigen (BCMA), and BAFF receptor (BAFF-R) with different affinities.

Medshine Discovery has patented pyrimidopyran-containing compounds acting as GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

Suzhou Kowloon Hospital Shanghai Jiao Tong University School of Medicine has divulged new Toll-like receptor 7 (TLR-7) agonists reported to be useful for the treatment of cancer and viral infections.